Search hospitals > New York > Commack
Memorial Sloan Kettering Commack
Claim this profileCommack, New York 11725
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Stomach Cancer
682 reported clinical trials
190 medical researchers
Summary
Memorial Sloan Kettering Commack is a medical facility located in Commack, New York. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Lymphoma, Stomach Cancer and other specialties. Memorial Sloan Kettering Commack is involved with conducting 682 clinical trials across 626 conditions. There are 190 research doctors associated with this hospital, such as Christopher J. Forlenza, Thomas Kaley, MD, Alan L Ho, MD, PhD, and Andrea Cercek, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 positive
HER2 negative
Top PIs
Christopher J. ForlenzaMemorial Sloan Kettering Cancer Center7 years of reported clinical research
Expert in Lymphoma
Expert in Langerhans Cell Histiocytosis
18 reported clinical trials
38 drugs studied
Thomas Kaley, MDMemorial Sloan Kettering Cancer Center6 years of reported clinical research
Studies Brain Tumor
Studies Cerebral Gliomas
15 reported clinical trials
23 drugs studied
Alan L Ho, MD, PhDMemorial Sloan Kettering Cancer Center1 year of reported clinical research
Studies Skin Cancer
Studies Thyroid Cancer
16 reported clinical trials
26 drugs studied
Andrea Cercek, MDMemorial Sloan Kettering Cancer Center2 years of reported clinical research
Studies Colorectal Cancer
Studies Rectal Cancer
15 reported clinical trials
32 drugs studied
Clinical Trials running at Memorial Sloan Kettering Commack
Skin Cancer
Esophageal Adenocarcinoma
Lung Cancer
Esophageal Carcinoma
Breast Cancer
Ovarian Cancer
Gastroesophageal Junction Adenocarcinoma
Lymphoma
Esophageal cancer
Salivary Gland Cancer
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Memorial Sloan Kettering Commack?
Memorial Sloan Kettering Commack is a medical facility located in Commack, New York. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Lymphoma, Stomach Cancer and other specialties. Memorial Sloan Kettering Commack is involved with conducting 682 clinical trials across 626 conditions. There are 190 research doctors associated with this hospital, such as Christopher J. Forlenza, Thomas Kaley, MD, Alan L Ho, MD, PhD, and Andrea Cercek, MD.
Where is Memorial Sloan Kettering Commack located?
Memorial Sloan Kettering Commack is situated at 650 Commack Road, Commack, NY 11725. Access is convenient via the Long Island Expressway (I-495), taking Exit 53 and proceeding north on Commack Road, where the hospital is located on the right side.
Who should I call to ask about financial aid or insurance network?
**Memorial Sloan Kettering Commack Hospital Contact Information:**
- **Financial Assistance:** Call Patient Financial Services at 212-639-3810 or visit a representative at:
- Rockefeller Outpatient Pavilion, 160 East 53rd Street, 3rd floor
- 64th Street Outpatient Center, 205 East 64th Street, Lower Concourse
- Evelyn H. Lauder Breast Center, 300 East 66th Street, 1st Floor
- The Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, 1st floor
- Main Hospital, 1275 York Ave, Room A104 (near the 67th Street entrance)
- **Insurance Questions:** Call Patient Billing Services at 646-497-9176 or email [billing@mskcc.org](mailto:billing@mskcc.org).
- **Prescription Assistance Programs:** Contact your doctor’s office to meet with your Patient Access Coordinator.
- **International Patients:** Call the International Center at 212-639-4900 or use AT&T Direct Access by dialing the access number for your country, then 888-675-7722.
- **General Inquiries:** Call 212-639-2000.
What insurance does Memorial Sloan Kettering Commack accept?
Memorial Sloan Kettering Cancer Center (MSK) accepts a variety of insurance plans, including but not limited to Medicare, Medicaid, and commercial plans from Aetna, Blue Cross Blue Shield, Cigna, and many others. It's important to verify that your specific plan includes MSK in its network by reviewing the list of participating insurance plans or contacting MSK directly. Patients are also encouraged to confirm their coverage and financial responsibility with their insurance company.
What awards or recognition has Memorial Sloan Kettering Commack received?
Memorial Sloan Kettering Cancer Center, including its Commack location, is celebrated for its pioneering research and exceptional patient care, emphasizing safety and innovative treatments. The center's scientists are recipients of prestigious awards, such as the Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grants. It boasts one of the country's largest clinical trials programs for cancer, offering patients early access to the latest treatments.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.